Day: February 4, 2022

Dose selection complete for planned Phase 3 trial, expected to be initiated in 3Q2022 Sub-analysis compared the immunogenicity of VLA15 in adults 18-65 years of age after administration of two or three primary series doses Stronger immune response observed in adult participants who received three priming doses vs. two priming doses; pediatric study ongoing with initial data expected in 1H2022 Three-dose priming schedule selected for use in adults moving forwardSaint-Herblain (France) and New York, February 4, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and Pfizer Inc. (NYSE: PFE) today reported further positive Phase 2 data for their Lyme disease vaccine candidate, VLA15. Based on these new results, Valneva and Pfizer plan to proceed with a three-dose primary series vaccination schedule in a planned...

TORONTO, Feb. 03, 2022 (GLOBE NEWSWIRE) — Rogers Communications Inc. (“RCI”) announced today that it has priced a private offering of US$750 million aggregate principal amount of 5.25% fixed-to-fixed rate subordinated notes due 2082 (the “Notes”). The net proceeds from the issuance of the Notes will be approximately US$740 million. RCI expects to use these net proceeds to repay a portion of its senior notes maturing this year and/or certain short-term borrowings that were used to fund, in part, its acquisition of 3500 MHz spectrum licenses in 2021. The offering of the Notes is expected to close on February 11, 2022. The Notes will not be registered under the Securities Act of 1933, as amended (the “Securities Act”), or any state securities laws in the United States and may not be offered or sold in the United States...

NEW YORK, Feb. 03, 2022 (GLOBE NEWSWIRE) — On February 2, 2022, Exelon Corp. (Nasdaq: EXC) announced it completed the separation of Constellation Energy Corp. (Nasdaq: CEG), Exelon’s former power generation and competitive energy business. Upon the completion of this spin-off transaction, Constellation Energy Corp. was added to the NASDAQ-100 Index® (Nasdaq: NDX), the NASDAQ-100 Equal Weighted Index (Nasdaq: NDXE) and the NASDAQ-100 Ex-Technology Index (Nasdaq: NDXX) on February 2, 2022. After review, Nasdaq has determined that Constellation Energy Corp. will remain as a component of the NASDAQ-100 Index®, the NASDAQ-100 Equal Weighted Index and the NASDAQ-100 Ex-Technology Index. For more information about the company, go to https://www.constellationenergy.com/ About Nasdaq Nasdaq (Nasdaq: NDAQ) is a global technology company...

VANCOUVER, British Columbia, Feb. 03, 2022 (GLOBE NEWSWIRE) — Diversified Royalty Corp. (TSX: DIV and DIV.DB) (the “Corporation” or “DIV”) is pleased to announce the preliminary results for its royalty partners for the three months ended December 31, 2021 (“Q4 2021”). Mr. Lube Fourth Quarter Results Mr. Lube Canada Limited Partnership (“Mr. Lube”) generated same-store-sales-growth (“SSSG”) of 20.7% for the Mr. Lube stores in the royalty pool for Q4 2021, compared to SSSG of 1.1% for the three months ended December 31, 2020 (“Q4 2020”). Mr. Lube generated SSSG of 15.8% for the Mr. Lube stores in the royalty pool for the twelve months ended December 31, 2021, compared to SSSG of -4.4% for the twelve months ended December 31, 2020. Mr. Lube generated SSSG of 21.5% and 10.4% for the Mr. Lube stores in the royalty pool for the three...

VANCOUVER, British Columbia, Feb. 03, 2022 (GLOBE NEWSWIRE) — XR Immersive Tech Inc. (“Immersive Tech”, or the “Company”) (CSE:VRAR) (FSE:79W) (OTCQB: FNTTF) is pleased to announce that on January 19, 2022, it filed two full patent applications for its patent-pending technology with the Canadian Intellectual Property Office. These applications add to the Company’s growing patent portfolio as the Company has previously filed U.S. provisional patent applications for its technology. The Company elected to file these Canadian patent applications in priority to U.S. Patent office filings, to further protect its valuable intellectual property (“IP”) as it continues to innovate and pursue development of cutting edge VR/AR technology to support sales growth and opportunities for both clients looking to provide hyper-immersive experiences...

First-ever lentiviral hematopoietic stem cell gene therapy approved for reimbursement by NHS England Two children with early-onset MLD recently treated commercially with Libmeldy in Germany and France A third eligible patient identified through partnership in Middle East and referred for international reimbursed treatment abroad in Italy Announcements mark significant milestones for the MLD community and reinforce growing momentum of European launch BOSTON and LONDON, Feb. 03, 2022 (GLOBE NEWSWIRE) — Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced it has reached an agreement with the National Health Service (NHS) that enables access to Libmeldy® (atidarsagene autotemcel) for all children with metachromatic leukodystrophy (MLD) in England and Wales who fall within the scope of the European marketing...